TK1-Targeted CARs and BiTEs for Cancer Immunotherapy ID: 2015-046
An innovative approach leveraging Thymidine Kinase 1 (TK1) as a target for cancer immunotherapy using CARs and BiTEs.
Photo by starlineart - stock.adobe.com
Technology Overview
This technology involves the development of Chimeric Antigen Receptors (CARs) and Bispecific T-cell Engagers (BiTEs) that utilize single-chain variable fragments (scFvs) derived from monoclonal antibodies specific to TK1. By targeting TK1, which is overexpressed on the surface of cancer cells but not on normal cells, this approach aims to direct T cells to selectively destroy cancer cells, offering a promising avenue for cancer treatment.
Key Advantages
- High specificity towards cancer cells due to targeting TK1, a biomarker not found on normal cells
- Potential for broad application across various types of cancers
- Minimized off-target effects through the use of engineered T cells
- Enhanced anti-tumor activity by leveraging the body's own immune system
Problems Addressed
- Limited specificity and potential side effects of current cancer therapies
- Challenges in targeting a wide range of cancers with a single therapeutic approach
- Need for more effective and less harmful cancer treatment options
Market Applications
- Targeted cancer therapy for various malignancies
- Development of next-generation immunotherapy treatments
- Combinatorial approaches with existing cancer treatments to enhance efficacy
- Personalized medicine through the development of patient-specific T cell therapies
Additional Information
Technology ID: 2015-046
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 28 March, 2025
Connect with the Tech Transfer to:
- Meet with the technology manager
- Receive additional information
- Request a marketing plan report